BridgeBio Pharma Financial Statements
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:47 PM ET
BridgeBio Pharma revenue and earnings
In fiscal 2025, BridgeBio Pharma generated $502.1 million in revenue, up 126.3% from fiscal 2024, its 2nd consecutive year of revenue growth. BridgeBio Pharma reported a net loss of $732.9 million, compared with a loss of $543.3 million a year earlier. Gross margin was 95.8% (down from 98.3%) and operating margin -104.2%.
Diluted earnings per share came in at -$3.78. Over the last 5 fiscal years, BBIO's revenue has grown at a 127.4% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
BridgeBio Pharma income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 502.08M | 221.90M | 9.30M | 77.65M | 69.72M | 8.25M | 40.56M | — | — |
| Revenue growth (YoY) | +126.26% | +2285.27% | -88.02% | +11.38% | +745.14% | -79.66% | — | — | — |
| Cost of Revenue | 20.96M | 3.88M | 2.45M | 3.43M | 3.11M | — | — | — | — |
| Gross Profit | 481.11M | 218.02M | 6.86M | 74.21M | 66.60M | — | — | — | — |
| Operating Expenses | 1.00B | 811.00M | 614.23M | 586.42M | 643.23M | 482.73M | 306.80M | 183.66M | 43.86M |
| Research & Development | 451.95M | 506.46M | 455.71M | 399.46M | 451.02M | 337.05M | 209.95M | 140.07M | 30.56M |
| Selling, General & Admin | 531.23M | 288.93M | 150.59M | 143.19M | 192.21M | 145.68M | 94.35M | — | — |
| Operating Income | -523.41M | -592.97M | -607.37M | -512.20M | -576.63M | -474.48M | -266.24M | -183.66M | -43.86M |
| Interest Expense | 53.10M | 90.99M | 81.29M | 80.44M | 46.78M | 36.66M | 8.77M | 2.55M | 13.00K |
| Other Income (Expense) | -209.09M | 50.78M | -45.88M | 27.55M | -9.82M | -31.01M | -22.34M | 14.21M | 26.00K |
| Pretax Income | -732.50M | -542.19M | -653.25M | -484.65M | -586.48M | 505.49M | 288.58M | 169.45M | 43.83M |
| Income Tax | 435.00K | 1.15M | 0 | 0 | — | — | — | — | — |
| Net Income | -732.94M | -543.35M | -653.25M | -484.65M | -586.45M | -505.49M | -288.58M | -169.45M | -43.83M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | -2.12 | -1.00 |
| EPS (Diluted) | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | -2.12 | -1.00 |
| Shares Outstanding (Basic) | 191.53M | 186.08M | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 61.77M | 30.60M |
| Shares Outstanding (Diluted) | 191.53M | 186.08M | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 61.77M | 30.60M |
| EBITDA | -517.98M | -586.90M | -600.88M | -505.43M | -570.79M | -473.03M | -265.38M | — | — |
| Gross Margin | 95.82% | 98.25% | 73.71% | 95.58% | 95.53% | — | — | — | — |
| Operating Margin | -104.25% | -267.22% | -6528.75% | -659.65% | -827.12% | -5751.99% | -656.41% | — | — |
| Net Margin | -145.98% | -244.86% | -7021.94% | -624.17% | -841.20% | -6127.87% | -711.50% | — | — |
This table shows 9 annual periods of BridgeBio Pharma's income statement, from FY 2025 back to FY 2017, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BBIO's reporting calendar. What is a income statement?